Community

Our community narratives are driven by numbers and valuation.

Value any stock for free in seconds

Get alerts and valuation updates

Participate in discussions

Weekly Picks

US$152.76
FV
25.3% undervalued intrinsic discount
16.00%
Revenue growth p.a.
6users have liked this narrative
0users have commented on this narrative
22users have followed this narrative
3 days ago author updated this narrative
US$151.43
FV
31.4% undervalued intrinsic discount
3.00%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
12 days ago author updated this narrative
€75.00
FV
50.8% undervalued intrinsic discount
26.69%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
14 days ago author updated this narrative
₦44.00
FV
19.1% overvalued intrinsic discount
17.49%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
14 days ago author updated this narrative
₦3.00
FV
12.7% undervalued intrinsic discount
11.90%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
14 days ago author updated this narrative
US$300.00
FV
21.4% undervalued intrinsic discount
9.04%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
15 days ago author updated this narrative
CC logo
Chemours
WA
WaneInvestmentHouse
Community Contributor

Chemours projects $825M-$975M adjusted EBITDA for 2025 with focus on cost savings

The Chemours Company ( CC ), a global chemistry company with leading market positions in Thermal & Specialized Solutions (“TSS”), Titanium Technologies (“TT”), and Advanced Performance Materials (“APM”), today announced its financial results for the fourth quarter and full year 2024. Key Fourth Quarter 2024 Results & Highlights Net Sales of $1.4 billion, in line with the corresponding prior-year quarter, with TSS achieving record fourth quarter Net Sales, driven by year-over-year growth of 23% in Opteon™ Refrigerants Net Loss attributable to Chemours of $8 million, or $0.05 per diluted share, compared with a Net Loss attributable to Chemours of $18 million, or $0.12 per diluted share, in the corresponding prior-year quarter Adjusted Net Income1 of $16 million, or $0.11 per diluted share, compared with $46 million, or $0.31 per diluted share, in the corresponding prior-year quarter Adjusted EBITDA1,2 of $179 million compared to $176 million in the corresponding prior-year quarter Cash returned to shareholders through dividends of $36 million in the quarter Key Full Year 2024 Results & Highlights Net Sales of $5.8 billion compared to $6.1 billion in the prior year Net Income attributable to Chemours of $86 million, or $0.57 per diluted share, compared with a Net Loss attributable to Chemours of $238 million, or $1.60 per diluted share, in the prior year3 Adjusted Net Income1 of $182 million, or $1.21 per diluted share, compared to $425 million, or $2.82 per diluted share, in the prior year3 Adjusted EBITDA1,2 of $786 million compared to $1.0 billion in the prior year Cash returned to shareholders through dividends of $148 million in the year Established new executive leadership team and announced Chemours’ Pathway to Thrive strategy to drive shareholder value Announced PCC Group’s plans to build a chlor-alkali facility at Chemours’ TiO2 plant in DeLisle, Mississippi and completed our planned Opteon™ YF expansion at Corpus Christi, Texas Fully remediated all four material weaknesses in internal control previously identified in the 2023 Form 10-K Full Year 2025 Outlook4 Adjusted EBITDA between $825 million and $975 million Capital expenditures between $250 million to $300 million
View narrative
US$21.07
FV
33.1% undervalued intrinsic discount
11.25%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
15 days ago author updated this narrative
€101.17
FV
0.07% undervalued intrinsic discount
0.01%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
16 days ago author updated this narrative
SEK 48.17
FV
25.1% undervalued intrinsic discount
6.00%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
16 days ago author updated this narrative
CA$5.00
FV
97.6% undervalued intrinsic discount
0%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
16 days ago author updated this narrative